Yissum - Research Development Company of the Hebrew University

Platform for Neutrophil Specific Targeting as a Mode of Immunotherapy

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

Dr. Zvika Granot, from the School of Medicine-IMRIC-Developmental Biology and Cancer Research, is working on a innovative approach for Neutrophil specific targeting of TGF-beta signaling as a novel anti-cancer therapy (see attached summary and several papers)
Project ID : 6-2015-4241

Yissum - Research Development Company of the Hebrew University

Description of the technology

Background

Neutrophils are potent effector cells in a wide number of infectious, inflammatory and cancerous conditions. Modulation of Neutrophil functions in these conditions may have significant therapeutic benefits and effects on disease progression. However, Neutrophils are short lived and cannot be manipulated ex-vivo. Neutrophil specific targeting allows modulation of neutrophil function in patients with minimal off-target effects.

Our Innovation

  • Using Neutrophil-Specific Nanoparticles to modify Neutrophil function as a mode of Immunotherapy.
  • We identified Neutrophil specific binding peptides.
  • PLGA nanoparticles decorated with these peptides are taken up specifically by neutrophils.
  • Drug containing nanoparticles modify neutrophil function.
  • Targeted neutrophils accumulate in site of disease.
  • Neutrophil specific targeting of TGFbeta blocks metastatic progression.

Application

The neutrophil specific platform may be used to modulate neutrophil function using drugs that may have adverse consequences when administered systemically. Using this platform of very low drug concentrations will have the desired effect while having minimal to no off target effects.

Neutrophils accumulate and play a critical role in a wide range of clinical settings. Accordingly, while our proof of concept shows efficacy in a preclinical model of metastasis,modulating neutrophil function specifically using this platform may be used to treat many other conditions where neutrophils play a role such as COPD, Neutrophilic Asthma, Sepsis, Neutrophil dematoses, Stroke, etc.

Technology

We have identified peptides binding specifically to neutrophils in both mouse and human. We use these peptides to decorate PLGA nanoparticles which may contain any desirable payload. These nanoparticles are taken up specifically by neutrophils in vivo (A and B) and accumulate at sites of inflammation. Accordingly, neutrophil specific nanoparticles may be used to modulate neutrophil function in vivo. As a proof of concept we tested the consequences of blocking TGFbeta in neutrophils in a preclinical model of metastatic breast cancer. Neutrophil specific nanoparticles containing SB431542 (a TGFbeta blocker) efficiently block the phosphorylation of Smad2 (C) – an indication for activation of canonical TGFbeta signaling. When introduced into the circulation of mice with mammary tumor lung metastases, nanoparticles containing TGFbeta blocker dramatically reduced metastatic outgrowth (E and F).

Project manager

Shani Bullock
VP, Business Development, Healthcare

Project researchers

Zvi Granot
HUJI, School of Medicine - IMRIC
Developmental Biology and Cancer Research

Related keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Diagnostic
  • Therapeutic
  • Other Medical/Health Related
  • Agro and Marine biotech
  • Anatomy, Pathology, Immunology, Physiology
  • Clinical Medicine
  • Life Science & Biotechnology
  • Oncology / Cancer

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.